ARCHIVES

Phase III Nexavar Trial Fails Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 8 | August 29, 2014

Download PDF Visit The Full Archive

Related Articles

USC wins $3.5 million NCI grant.

April 23, 2004

Bills Would Give FDA Authority to Approve Generic Biotech Drugs.

February 16, 2007

Funding Opportunities.

May 31, 2002

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

DCCR Merit Review Finds some Excellent contract Projects, Some Not So Good; Some Are Terminated

February 25, 1977

ASCO Highlights Six Studies From Meeting To Showcase Advances In Cancer Care

May 30, 2008